LGALS3 and neoplasm: This result unbiasedly validates that GPVI–galectin-3 interaction is pivotal in platelet-mediated tumor promotion and establishes the therapeutic efficacy of antiplatelet drug Revacept against the progression of cancer with this preclinical platform.